lipid and survival problem caused by hiv drugs

some NRTI impact lipid levels, and when used long-term cause cardiovascular problems

ATC has NO detectable impact on lipid levels! so can be used long-term with little risk!


"Assessing and Managing Cardiovascular Risk in Patients with HIV"
Presented by: The Johns Hopkins University School of Medicine
Release Date: January 20, 2011

In the past several years, compelling evidence implicates HIV itself as a risk factor for atherosclerosis and premature coronary artery disease. In addition, specific antiretroviral therapy agents have been identified as potential contributors to cardiovascular risk, either by worsening traditional risk factors such as dyslipidemia, or directly by unclear mechanisms. These newer findings stand on the backdrop of increasing lifespan among people living with HIV who receive long-term antiretroviral therapy. As a result, cardiovascular disease is now the 3rd or 4th leading cause of death among people living with HIV. However, similar to the general population, management of modifiable risk factors can significantly reduce the risk of myocardial infarction in people living with HIV. This case study will explore issues in cardiovascular risk and risk modification among persons living with HIV.